ArticleJournal of neurology2025
Subjective psychiatric symptoms in post-acute autoimmune encephalitis: findings from the Australian autoimmune encephalitis consortium.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A new Patient-Reported Outcome Scale to assess autoimmune Encephalitis: PROSE.Annals of neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Funding
Abstract
BACKGROUND AND
objectivesThis study examined self-reported psychopathology in patients with autoimmune encephalitis (AE), and explored their relationship with clinical outcomes as measured by the modified Rankin Scale (mRS) and Clinical Assessment Scale in Autoimmune Encephalitis (CASE) scores.
methodsEighty-seven AE patients (49.43% female, mean age = 54.47 years, SD = 17.84) from the Australian Autoimmune Encephalitis Consortium completed the SPECTRA-Indices of Psychopathology, time-matched with CASE and mRS scores within six months of the assessments.
resultsOn average, assessments occurred 12 months post-onset. Median CASE and mRS scores were 2, with 84.13% of patients scoring mRS ≤ 2. Mean SPECTRA scores were significantly elevated across multiple domains, indicating greater psychopathology, particularly in depression, post-traumatic stress, suicidal ideation, and cognitive functioning. Patients with seronegative AE exhibited more severe psychopathology compared to those with anti-N-methyl-D-aspartate receptor (NMDAR) and anti-leucine-rich glioma-inactivated 1 (LGI1) subtypes. Psychiatric diagnoses prior to AE onset were associated with worse outcomes, compared to those with no pre-existing psychiatric conditions and those diagnosed post-onset. The mRS and CASE scores each explained only a small amount of variance (7-26%) across SPECTRA domains, and adding the other score to the model provided only little improvement. DISCUSSION: AE patients exhibit significant psychopathology across multiple domains, with significant internalising symptoms-including depression, post-traumatic stress, and suicidal ideation-as well as cognitive concerns, highlighting the considerable psychiatric burden in this population. Our findings highlight the need for systematic, timely assessments of psychological symptoms in AE, and the use of sensitive, comprehensive instruments to capture the full spectrum of their psychopathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.